Search

Displaying results 1971 - 1980 of 4600 in total
  1. Drug

    Risedronic acid

    go.drugbank.com/drugs/DB00884
    ApprovedInvestigational

    It functions by preventing resorption of bone[FDA Label][A959].

  2. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264254] By binding to IL-31RA, nemolizumab blocks the IL-31 signalling cascades that lead to inflammation. … [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169]

  3. Drug

    Upinitatug rilsodotin

    go.drugbank.com/drugs/DB19104
    Investigational

    Upinitatug rilsodotin is under investigation in clinical trial NCT05329545 (Upifitamab Rilsodotin Maintenance in Platinum-sensitive Recurrent Ovarian Cancer (UP-NEXT)).

  4. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

  5. Drug

    Prednicarbate

    go.drugbank.com/drugs/DB01130
    Approved

    It has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy.

  6. Drug

    Teriflunomide

    go.drugbank.com/drugs/DB08880
    ApprovedInvestigational

    Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.

  7. Drug

    Bambuterol

    go.drugbank.com/drugs/DB01408
    Investigational

    Bambuterol is a long acting beta-adrenoceptor agonist used in the treatment of asthma. It is a prodrug of terbutaline.

  8. Drug

    Sotatercept

    go.drugbank.com/drugs/DB12118
    ApprovedInvestigational

    [A263481] Sotatercept was approved by the European Commission on August 26, 2024.[L51549] … [L50351] On March 26, 2024, sotatercept was approved by the FDA for the treatment of pulmonary arterial hypertension (PAH).

  9. Drug

    Nimacimab

    go.drugbank.com/drugs/DB15115
    Investigational

    Nimacimab is under investigation in clinical trial NCT03261739 (Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)).

  10. Drug

    Sibeprenlimab

    go.drugbank.com/drugs/DB18919
    ApprovedInvestigational

    [A274853, A274858] Sibeprenlimab is a humanized immunoglobulin G2 (IgG2) monoclonal antibody produced by Chinese Hamster Ovary (CHO) cells. … [L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628]